Lilly's Zepbound beats Novo's CagriSema in head-to-head obesity trial
The direct comparison puts tirzepatide ahead of the cagrilintide-semaglutide combination as Novo Nordisk seeks approval for the injection.
MH
By Maren Holt · Senior Reporter, GLP-1
Feb 23 03:00 ETSource: Clinical Trials Arena
The wire
- 01Clinical Trials Arena reports that Novo Nordisk's CagriSema was outperformed by Eli Lilly's Zepbound (tirzepatide) in a head-to-head obesity trial.
- 02Head-to-head data carry more weight with payers and prescribers than cross-trial comparisons, and shape which incretin products telehealth operators stock.
- 03Detailed endpoint figures, dosing and tolerability data were not given in the report; Novo Nordisk's regulatory filing for CagriSema remains pending.
From the source
Read at clinicaltrialsarena.comNovo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial
